Pipeline
ABL102
HomePipelineABL102
-
- Pipeline
- ABL102
-
- Program Target
- ROR1x4-1BB
-
- Disease Indication
- Solid & Blood Tumor
-
- Development Stage
- IND enabling study
- Summary
- ABL102 is a bispecific antibody that simultaneously targets ROR1 and 4-1BB, activating 4-1BB signaling only in the presence of ROR1 expressing tumor cells. By having intact Fc, ABL102 activates T cells via FcyRI mediated 4-1BB clustering. Additionally, ABL102 induces intra-tumoral Treg depletion potentially via an ADCC activity, resulting in strong tumor growth inbihition. ABL102 significantly inhibits tumor growth and protects mice from tumor recurrence inducing tumor-specific immunological memory.
MOA of ABL102
ABL102 in the Grabody™-T BsAb Platform activates T-cells only in the tumor Microenvironment
